Helena Margaret Earl, MBBS, PhD, on Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer

Posted: Monday, June 4, 2018

Helena Margaret Earl, MBBS, PhD, of the University of Cambridge, discusses phase III study findings on 6 vs 12 months of adjuvant trastuzumab in patients with HER2-positive early breast cancer.